{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T20:28:16Z","timestamp":1781987296438,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T00:00:00Z","timestamp":1379548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10557-013-6490-9","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T06:17:44Z","timestamp":1379485064000},"page":"87-98","source":"Crossref","is-referenced-by-count":17,"title":["Cost\u2013Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting"],"prefix":"10.1007","volume":"28","author":[{"given":"Bin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Kun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"issue":"18","key":"6490_CR1","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.111.039677","volume":"124","author":"JW Magnani","year":"2011","unstructured":"Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, et al. Atrial Fibrillation Current Knowledge and Future Directions in Epidemiology and Genomics. Circulation. 2011;124(18):1982\u2013U170. doi: 10.1161\/circulationaha.111.039677 .","journal-title":"Circulation"},{"issue":"9","key":"6490_CR2","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","volume":"110","author":"DM Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042\u20136. doi: 10.1161\/01.CIR.0000140263.20897.42 .","journal-title":"Circulation"},{"issue":"8","key":"6490_CR3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949\u201353. doi: 10.1093\/eurheartj\/ehi825 .","journal-title":"Eur Heart J"},{"issue":"10","key":"6490_CR4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2008.05.042","volume":"52","author":"D Hu","year":"2008","unstructured":"Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol. 2008;52(10):865\u20138. doi: 10.1016\/j.jacc.2008.05.042 .","journal-title":"J Am Coll Cardiol"},{"issue":"8A","key":"6490_CR5","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","volume":"82","author":"WB Kannel","year":"1998","unstructured":"Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N\u20139N.","journal-title":"Am J Cardiol"},{"issue":"2","key":"6490_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","volume":"114","author":"Y Miyasaka","year":"2006","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119\u201325. doi: 10.1161\/CIRCULATIONAHA.105.595140 .","journal-title":"Circulation"},{"issue":"18","key":"6490_CR7","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama. 2001;285(18):2370\u20135.","journal-title":"Jama"},{"issue":"8","key":"6490_CR8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke; a journal of cerebral circulation. 1991;22(8):983\u20138.","journal-title":"Stroke; a journal of cerebral circulation"},{"issue":"10","key":"6490_CR9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","volume":"28","author":"PA Wolf","year":"1978","unstructured":"Wolf PA, Dawber TR, Thomas Jr HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28(10):973\u20137.","journal-title":"Neurology"},{"issue":"12","key":"6490_CR10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857\u201367.","journal-title":"Ann Intern Med"},{"issue":"3 Suppl","key":"6490_CR11","doi-asserted-by":"crossref","first-page":"429S","DOI":"10.1378\/chest.126.3_suppl.429S","volume":"126","author":"DE Singer","year":"2004","unstructured":"Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):429S\u201356S. doi: 10.1378\/chest.126.3_suppl.429S .","journal-title":"Chest"},{"issue":"17","key":"6490_CR12","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1002617","volume":"363","author":"DB Matchar","year":"2010","unstructured":"Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17):1608\u201320. doi: 10.1056\/NEJMoa1002617 .","journal-title":"N Engl J Med"},{"issue":"2","key":"6490_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.tpj.6500417","volume":"7","author":"M Wadelius","year":"2007","unstructured":"Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7(2):99\u2013111. doi: 10.1038\/sj.tpj.6500417 .","journal-title":"Pharmacogenomics J"},{"issue":"16","key":"6490_CR14","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/eurheartj\/ehr052","volume":"32","author":"J Steffel","year":"2011","unstructured":"Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J. 2011;32(16):1968\u201376. doi: 10.1093\/eurheartj\/ehr052 . 76a.","journal-title":"Eur Heart J"},{"issue":"10","key":"6490_CR15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. doi: 10.1056\/NEJMoa1009638 .","journal-title":"N Engl J Med"},{"issue":"5","key":"6490_CR16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14740338.2011.558500","volume":"10","author":"T Goff","year":"2011","unstructured":"Goff T, Kontakis G, Giannoudis PV. Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. Expert Opin Drug Saf. 2011;10(5):687\u201396. doi: 10.1517\/14740338.2011.558500 .","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"6490_CR17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amjcard.2013.03.054","volume":"112","author":"G Wasserlauf","year":"2013","unstructured":"Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ. Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol. 2013;112(3):454\u201360. doi: 10.1016\/j.amjcard.2013.03.054 .","journal-title":"Am J Cardiol"},{"issue":"6","key":"6490_CR18","doi-asserted-by":"crossref","first-page":"e39640","DOI":"10.1371\/journal.pone.0039640","volume":"7","author":"JH You","year":"2012","unstructured":"You JH, Tsui KK, Wong RS, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One. 2012;7(6):e39640. doi: 10.1371\/journal.pone.0039640 .","journal-title":"PLoS One"},{"key":"6490_CR19","author":"T Davidson","year":"2012","unstructured":"Davidson T, Husberg M, Janzon M, Oldgren J, Levin LA. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J. 2012. doi: 10.1093\/eurheartj\/ehs157 .","journal-title":"Eur Heart J"},{"issue":"7","key":"6490_CR20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/heartjnl-2011-300646","volume":"98","author":"AR Kansal","year":"2012","unstructured":"Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573\u20138. doi: 10.1136\/heartjnl-2011-300646 .","journal-title":"Heart"},{"issue":"3","key":"6490_CR21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1161\/STROKEAHA.111.641027","volume":"43","author":"H Kamel","year":"2012","unstructured":"Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke; a journal of cerebral circulation. 2012;43(3):881\u20133. doi: 10.1161\/STROKEAHA.111.641027 .","journal-title":"Stroke; a journal of cerebral circulation"},{"issue":"22","key":"6490_CR22","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","volume":"123","author":"SV Shah","year":"2011","unstructured":"Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562\u201370. doi: 10.1161\/CIRCULATIONAHA.110.985655 .","journal-title":"Circulation"},{"issue":"5","key":"6490_CR23","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1160\/TH11-02-0089","volume":"105","author":"SV Sorensen","year":"2011","unstructured":"Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908\u201319. doi: 10.1160\/TH11-02-0089 .","journal-title":"Thromb Haemost"},{"issue":"1","key":"6490_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","volume":"154","author":"JV Freeman","year":"2011","unstructured":"Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1\u201311. doi: 10.1059\/0003-4819-154-1-201101040-00289 .","journal-title":"Ann Intern Med"},{"issue":"6","key":"6490_CR25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.amjcard.2012.05.011","volume":"110","author":"S Lee","year":"2012","unstructured":"Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110(6):845\u201351. doi: 10.1016\/j.amjcard.2012.05.011 .","journal-title":"Am J Cardiol"},{"issue":"10","key":"6490_CR26","doi-asserted-by":"crossref","first-page":"e47473","DOI":"10.1371\/journal.pone.0047473","volume":"7","author":"S Lee","year":"2012","unstructured":"Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One. 2012;7(10):e47473. doi: 10.1371\/journal.pone.0047473 .","journal-title":"PLoS One"},{"issue":"14","key":"6490_CR27","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1212\/WNL.0b013e31826d5fe8","volume":"79","author":"H Kamel","year":"2012","unstructured":"Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79(14):1428\u201334. doi: 10.1212\/WNL.0b013e31826d5fe8 .","journal-title":"Neurology"},{"issue":"4","key":"6490_CR28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","volume":"16","author":"D Coyle","year":"2013","unstructured":"Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498\u2013506. doi: 10.1016\/j.jval.2013.01.009 .","journal-title":"Value Health"},{"issue":"6","key":"6490_CR29","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","volume":"44","author":"AR Harrington","year":"2013","unstructured":"Harrington AR, Armstrong EP, Nolan Jr PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676\u201381. doi: 10.1161\/STROKEAHA.111.000402 .","journal-title":"Stroke"},{"issue":"4","key":"6490_CR30","doi-asserted-by":"crossref","first-page":"e62183","DOI":"10.1371\/journal.pone.0062183","volume":"8","author":"BL Limone","year":"2013","unstructured":"Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One. 2013;8(4):e62183. doi: 10.1371\/journal.pone.0062183 .","journal-title":"PLoS One"},{"issue":"6","key":"6490_CR31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20133. Value Health. 2012;15(6):812\u201320. doi: 10.1016\/j.jval.2012.06.014 .","journal-title":"Value Health"},{"issue":"2","key":"6490_CR32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1258\/135581904322987535","volume":"9","author":"P Barton","year":"2004","unstructured":"Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9(2):110\u20138. doi: 10.1258\/135581904322987535 .","journal-title":"J Health Serv Res Policy"},{"issue":"9526","key":"6490_CR33","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903\u201312. doi: 10.1016\/S0140-6736(06)68845-4 .","journal-title":"Lancet"},{"issue":"8631","key":"6490_CR34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","volume":"1","author":"P Petersen","year":"1989","unstructured":"Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175\u20139.","journal-title":"Lancet"},{"issue":"16","key":"6490_CR35","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine. 2006;354(16):1706\u201317. doi: 10.1056\/NEJMoa060989 .","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"6490_CR36","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.158.14.1513","volume":"158","author":"AL Gullov","year":"1998","unstructured":"Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158(14):1513\u201321.","journal-title":"Arch Intern Med"},{"issue":"7282","key":"6490_CR37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bmj.322.7282.321","volume":"322","author":"FC Taylor","year":"2001","unstructured":"Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. Bmj. 2001;322(7282):321\u20136.","journal-title":"Bmj"},{"issue":"5","key":"6490_CR38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2188\/jea.JE2008021","volume":"18","author":"Z Zhou","year":"2008","unstructured":"Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol. 2008;18(5):209\u201316.","journal-title":"J Epidemiol"},{"issue":"22","key":"6490_CR39","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Jama. 2001;285(22):2864\u201370.","journal-title":"Jama"},{"key":"6490_CR40","doi-asserted-by":"crossref","unstructured":"Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005(3):CD001927. doi: 10.1002\/14651858.CD001927.pub2 .","DOI":"10.1002\/14651858.CD001927.pub2"},{"issue":"11","key":"6490_CR41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1474-4422(07)70264-8","volume":"6","author":"GY Lip","year":"2007","unstructured":"Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6(11):981\u201393. doi: 10.1016\/S1474-4422(07)70264-8 .","journal-title":"Lancet Neurol"},{"issue":"2","key":"6490_CR42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","volume":"18","author":"SJ Connolly","year":"1991","unstructured":"Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18(2):349\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"6490_CR43","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","volume":"360","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066\u201378. doi: 10.1056\/NEJMoa0901301 .","journal-title":"N Engl J Med"},{"issue":"11","key":"6490_CR44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","volume":"349","author":"EM Hylek","year":"2003","unstructured":"Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019\u201326. doi: 10.1056\/NEJMoa022913 .","journal-title":"N Engl J Med"},{"issue":"4","key":"6490_CR45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY Shen","year":"2007","unstructured":"Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309\u201315. doi: 10.1016\/j.jacc.2007.01.098 .","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"6490_CR46","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1161\/01.STR.0000080678.09344.8D","volume":"34","author":"MJ Ariesen","year":"2003","unstructured":"Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke; a journal of cerebral circulation. 2003;34(8):2060\u20135. doi: 10.1161\/01.STR.0000080678.09344.8D .","journal-title":"Stroke; a journal of cerebral circulation"},{"issue":"8","key":"6490_CR47","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","volume":"164","author":"J Rosand","year":"2004","unstructured":"Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral Hemorrhage. Arch Intern Med. 2004;164(8):880\u20134. doi: 10.1001\/archinte.164.8.880 .","journal-title":"Arch Intern Med"},{"issue":"2","key":"6490_CR48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Study","year":"1991","unstructured":"Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527\u201339.","journal-title":"Circulation"},{"issue":"4","key":"6490_CR49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0272989X10384738","volume":"31","author":"S Whyte","year":"2011","unstructured":"Whyte S, Walsh C, Chilcott J. Bayesian calibration of a natural history model with application to a population model for colorectal cancer. Med Decis Making. 2011;31(4):625\u201341. doi: 10.1177\/0272989X10384738 .","journal-title":"Med Decis Making"},{"issue":"8","key":"6490_CR50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archinternmed.2012.121","volume":"172","author":"S Agarwal","year":"2012","unstructured":"Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012;172(8):623\u201331. doi: 10.1001\/archinternmed.2012.121 . discussion 31\u20133.","journal-title":"Arch Intern Med"},{"issue":"5","key":"6490_CR51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCOUTCOMES.110.957613","volume":"3","author":"SM Bernheim","year":"2010","unstructured":"Bernheim SM, Grady JN, Lin Z, Wang Y, Savage SV, Bhat KR, et al. National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes. 2010;3(5):459\u201367. doi: 10.1161\/CIRCOUTCOMES.110.957613 .","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"6490_CR52","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1378\/chest.10-3024","volume":"140","author":"D Poli","year":"2011","unstructured":"Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest. 2011;140(4):918\u201324. doi: 10.1378\/chest.10-3024 .","journal-title":"Chest"},{"issue":"32","key":"6490_CR53","first-page":"2527","volume":"20","author":"Z Ce","year":"2009","unstructured":"Ce Z. Anticoagulation Efficacy of Warfarin: Analysis of 95 Cases. China Pharmacy. 2009;20(32):2527\u20139. doi: 1001-0408(2009)20:32<2527:9lhzhf>2.0.tx;2-y .","journal-title":"China Pharmacy"},{"key":"6490_CR54","unstructured":"Life tables for WHO Member States. http:\/\/www.who.int\/healthinfo\/statistics\/mortality_life_tables\/en\/ . Accessed 2012 September 18."},{"issue":"11","key":"6490_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8110","volume":"8","author":"P Barton","year":"2004","unstructured":"Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction. Health Technol Assess. 2004;8(11):1.","journal-title":"Health Technol Assess"},{"issue":"6","key":"6490_CR56","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jama.293.6.699","volume":"293","author":"CL O'Brien","year":"2005","unstructured":"O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. Jama. 2005;293(6):699\u2013706. doi: 10.1001\/jama.293.6.699 .","journal-title":"Jama"},{"issue":"4","key":"6490_CR57","first-page":"262","volume":"27","author":"L Sui-feng","year":"2008","unstructured":"Sui-feng L, Zai-jin J, Min O. A warfarin-dosing algorithm on atrial fibrillation in elderly patients. Chinese Journal Of Geriatrics. 2008;27(4):262\u20135.","journal-title":"Chinese Journal Of Geriatrics"},{"issue":"5","key":"6490_CR58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518\u201328. doi: 10.1111\/j.1524-4733.2004.75003.x .","journal-title":"Value Health"},{"issue":"3","key":"6490_CR59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235\u201351.","journal-title":"Health Econ"},{"issue":"3","key":"6490_CR60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MLR.0b013e31820192cd","volume":"49","author":"FL Zhao","year":"2011","unstructured":"Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care. 2011;49(3):267\u201372. doi: 10.1097\/MLR.0b013e31820192cd .","journal-title":"Med Care"},{"issue":"3","key":"6490_CR61","doi-asserted-by":"crossref","first-page":"244","DOI":"10.18553\/jmcp.2009.15.3.244","volume":"15","author":"WL Baker","year":"2009","unstructured":"Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244\u201352.","journal-title":"J Manag Care Pharm"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-013-6490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-013-6490-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-013-6490-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T09:48:25Z","timestamp":1646560105000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-013-6490-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["6490"],"URL":"https:\/\/doi.org\/10.1007\/s10557-013-6490-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]}}}